1. Home
  2. HAFC vs REPL Comparison

HAFC vs REPL Comparison

Compare HAFC & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hanmi Financial Corporation

HAFC

Hanmi Financial Corporation

HOLD

Current Price

$25.03

Market Cap

758.9M

Sector

Finance

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$7.33

Market Cap

781.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HAFC
REPL
Founded
1982
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
758.9M
781.3M
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
HAFC
REPL
Price
$25.03
$7.33
Analyst Decision
Hold
Buy
Analyst Count
3
9
Target Price
$28.50
$12.00
AVG Volume (30 Days)
262.2K
1.5M
Earning Date
01-27-2026
02-06-2026
Dividend Yield
3.79%
N/A
EPS Growth
22.44
N/A
EPS
2.51
N/A
Revenue
$255,726,000.00
N/A
Revenue This Year
$19.61
N/A
Revenue Next Year
$11.05
N/A
P/E Ratio
$11.34
N/A
Revenue Growth
11.21
N/A
52 Week Low
$19.25
$2.68
52 Week High
$30.20
$14.80

Technical Indicators

Market Signals
Indicator
HAFC
REPL
Relative Strength Index (RSI) 30.19 36.15
Support Level $28.02 $7.39
Resistance Level $30.20 $7.80
Average True Range (ATR) 0.96 0.48
MACD -0.20 -0.01
Stochastic Oscillator 9.45 28.40

Price Performance

Historical Comparison
HAFC
REPL

About HAFC Hanmi Financial Corporation

Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: